AzTrials
AzTrials

Tibia FracturePhase 3NCT05000281

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures

A Phase 3 study testing Ibuprofen in people with Tibia Fracture, run by Major Extremity Trauma Research Consortium at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial. 1,000 patients with tibia fractures treated with intramedullary (IM) nail will be randomized into two treatment arms. The control arm will receive standard pain management and no NSAIDs. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Tibia Fracture
What is being tested?
Ibuprofen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,000 participants
Where
1 siteUnited States
Study dates
14 Sep 2021to Dec 2024
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients with open (Grade I, II, of IIIa) or closed tibia fractures treated with a nail.
  • Patients 18-80 years old inclusive.
  • Patients able to be followed at a Major Extremity Trauma \& Rehabilitation (METRC) facility for at least 12 months following injury

Who cannot join

  • Patient unable to provide informed consent
  • Patients who are current - intravenous drug user.
  • Patients with a history of allergy to the study drugs.
  • Patients unable to swallow oral medications or without functioning GI tract.
  • Patients with a history of gastrointestinal bleeds or gastric perforation.
  • Patients with a history of stroke or heart attack.
Show all 15Show fewer
  • Patients requiring an aspirin or NSAID regimen except for low dose aspirin, 81mg.
  • Patients with any bleeding disorders.
  • Patients with severe renal failure [glomerular filtration rate (GFR):<30]. Patients with moderate renal failure [GFR: 30-59] may participate in the study at a modified dose.
  • Patients undergoing daily treatment with systemic glucocorticoids before surgery.
  • Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.
  • Patients with a Glasgow Coma Scale (GCS) <15 at discharge.
  • Patients with a closed head injury that precludes NSAIDS.
  • Patients who are pregnant or lactating at time of screening
  • Patients with a bone graft procedure planned for a future date at the time of initial definitive fixation surgery.

Trial locations and contacts

1 site in 1 country.

Tara Taylor Joseph, MPH contact

410-614-6081

ttaylo56@jhu.edu

Trisha Chaffee contact

tchaffe2@jhmi.edu

United States1 site, 1 recruiting
  • University of Utah

    Salt Lake City, Utah, 841112

    Zach Olsen, MD, zachary.olsen@hsc.utah.edu

    Sofia Hill, sophia.hill@hsc.utah.edu

    Recruiting

Other trials in United States

About this study

Official title: Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial. 1,000 patients with tibia fractures treated with intramedullary (IM) nail will be randomized into two treatment arms. The control arm will receive standard pain management and no NSAIDs. The treatment arm will receive standard pain management plus up to six weeks of NSAIDs (3 weeks of prescribed medication followed by 3 weeks of medication PRN).

Read the detailed description

The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial. Patients with diaphyseal tibia fractures treated with intramedullary (IM) nail will be randomized into two treatment arms. The control arm will receive standard pain management with no NSAIDs. The treatment arm will receive standard pain management plus up to six weeks of NSAIDs (3 weeks of prescribed medication followed by 3 weeks of medication PRN).

The hypothesis is that pain management using up to 6 weeks of NSAIDs will result in improved pain control and lower opioid consumption but demonstrate non-inferior levels of complications compared to standard of care pain management. The aim of the study is to:

Specific Aim: Evaluate the effect of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.

Primary Hypothesis: When compared to patients who received standard of care pain management, patients treated with up to 6 weeks of NSAIDs will have noninferior rates of surgery for to promote union at one year.

Secondary Hypotheses: When compared to patients who received standard of care pain management without NSAIDs, patients treated with up to 6 weeks of NSAIDs will benefit from (1) reduced opioid utilization; (2) reduced levels of persistent pain; (3) reduced pain interference; (4) improved functional outcomes; (5) noninferior rates of analgesic treatment related side effects; and (6) noninferior rates of radiographic union.

Study design: At time of IM nailing surgery for acute diaphyseal tibia fracture, patients will be randomized to treatment or control group. Treatment patients will receive a standard of care pain regimen and oral ibuprofen 600 mg three times a day (tid) for up to six weeks (3 weeks of prescribed medication followed by 3 weeks of medication PRN). Control patients will receive a standard of care pain regimen prescribed by the treating physician and may not use NSAIDs. Patients in both arms will be permitted to receive 81mg of daily aspirin. Patient medication adherence will be documented via an electronic data collection interface through mobile or web-based application. Patients who do not have access to documenting adherence electronically will be given paper-based medication dairies by the research team.

Follow-Up: Clinical, functional, and radiographic follow-up will be conducted at typical standard of care intervals of 2-3 weeks, 6 weeks, 3 months, 6 months, and one year.

Study duration: 3.75 years (18 month accrual, 24 month final follow-up, 3 month analysis and writing).

Sample size: 1,000 (500 per arm (2) arms)

Number of study sites: 14 sites (13 Civilian and 1 Military Treatment Facility)

Study population: The study population will consist of a relatively homogeneous group of 1,000 patients with orthopaedic trauma: patients with open or closed diaphyseal tibia fractures. Since military combat injuries are typically open, open fractures will be included in this study. However, since post-surgical pain after these injuries is not limited to the open fractures, and the practices of pain management should apply to both open and closed injuries, closed versions of these high energy injuries in the study population will also be included.

Conditions
Tibia Fracture
Being tested
Ibuprofen
Keywords
NSAID, Nonsteroidal Anti-Inflammatory Drug, Pain Interference, Persistent Pain, Pain Control, Opioid Utilization, Nonunion Surgery, Fracture Healing, Orthopaedic trauma
Medical subject headings
Tibial Fractures, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IbuprofenDrug

    Also called Advil, Motrin

    600 mg Ibuprofen 3 times a day for up to six weeks.

Study groups in NCT05000281
Study groupRoleWhat they receive
NSAIDExperimentalStandard of care pain medication regimen with NSAIDs.
Receives: Drug: Ibuprofen
No NSAIDsNo interventionStandard of care pain medication regiment with no NSAIDs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Numbers of participants with nonunion (secondary surgery to promote union)

    Nonunion will be assessed by the presence of a secondary surgery to promote union after 3 months post definitive fixation surgery. Surgery operative notes and radiographs of each case will be independently reviewed by members of the METRC Central Adjudication Committee and if at least 2 members agree with the assessment of secondary surgery to promote union, no further review will be necessary. The METRC Central Adjudication Committee will convene to discuss the cases for which there is disagreement regarding nonunion assessment.

    Measured: Between 3 months and 12 months after definitive fixation surgery

Secondary outcomes (4)
  1. Pain as assessed by the Brief Pain Inventory (BPI)

    The Brief Pain Inventory (BPI) is a widely used, 15-item measure of pain intensity and interference with daily life and will be assessed at baseline, 3, 6, and 12 months post definitive fixation surgery. It has been extensively validated in both English and Spanish, and also includes questions about pain treatments and the effectiveness of these treatments.46 The BPI pain intensity domain is compatible with the IMMPACT guidelines for assessing pain in clinical trials and the FDA Guidance for Industry on the use of Patient-Reported Outcome Measures.

    Measured: Baseline, 3, 6, 12, months

  2. Pain interference as assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference

    One of the domains assessed by The Patient Report Outcomes Measurement Information System (PROMIS) Computer Adaptive Test (CAT) includes Pain Interference. CATs present an advantage over traditional measures in that they target only the most relevant items to each patient and can thus be used to obtain precise measurements with 4-6 items, making assessment across multiple domains feasible. CATs can also extend the ceiling and floor of individual domains, potentially enhancing responsiveness.

    Measured: Baseline, 3, 6, 12, months

  3. Physical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS)

    Self -Reported Measures of Physical and Psychosocial Function will be assessed using the Patient Report Outcomes Measurement Information System (PROMIS) Computer Adaptive Test (CAT) item banks, a product of the NIH Roadmap for Medical Research. CATs present an advantage over traditional measures in that they target only the most relevant items to each patient and can thus be used to obtain precise measurements with 4-6 items, making assessment across multiple domains feasible. In this study the following PROMIS domains will be used: Physical function, Depression, Anxiety, Pain Inference, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities and Psychosocial Illness Impact.

    Measured: Baseline, 3, 6, 12, months

  4. Radiographic union as assessed by the modified Radiographic Union Scale in Tibial Fractures (mRUST)

    Radiographic union will be based on the modified RUST(mRUST) score assessed between 3 months and 12 months after definitive fixation surgery. The four cortices of the tibia fracture will be assessed and given a score from 1-4, 1=not healed, 4=healed. The mRUST score is the sum of the 4 cortical scores (4-16) and a score of 13 or greater is considered a healed fracture.

    Radiographic examinations at 3, 6 and 12 months by an adjudication committee comprised of METRC investigators will be evaluated based on AP and lateral x-rays.

    Measured: Between 3 months and 12 months after definitive fixation surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Aug 2021
  2. Study start14 Sep 2021
  3. Primary completionSep 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05000281
Sponsor's protocol ID
W81XWH2020063
Status last verified
Oct 2021
First submitted
3 Aug 2021
Last updated
6 Oct 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ibuprofen in people with Tibia Fracture, run by Major Extremity Trauma Research Consortium at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tara Taylor Joseph, MPH (410-614-6081, ttaylo56@jhu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Numbers of participants with nonunion (secondary surgery to promote union) (time frame: Between 3 months and 12 months after definitive fixation surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in